lisocabtagene maraleucel

targets

all catalysts(0)

nothing on the calendar yet

News(9)

• Unlocking cell surface protein research with site-specific labeling
  Applications in flow cytometry, cell sorting, target validation, and therapeutic discovery
  biospace · 19d ago
• Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
  BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.
  biospace · 1mo ago
• UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies
  Three deaths have forced Novartis to pause development of its CD19 CAR-T candidate in autoimmune diseases, just as Bristol Myers Squibb has halted a similar program due to immune-related adverse ev…
  fiercebiotech · 1mo ago
• BMS ends Cellares pact over cell therapy production problems, triggering layoffs
  Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its partnership with the manufacturing specialist.
  biospace · 1mo ago
• AstraZeneca scores in lung cancer; Sandoz inks a China deal
  A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.
  biopharma_dive · 1mo ago
• An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
  In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.
  biopharma_dive · 2mo ago
• Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
  Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
  biopharma_dive · 2mo ago
• Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
  Safety will be the key determinant of in vivo CAR T therapies, according to H.C. Wainwright’s Mitchel Kapoor, who noted that convenience and efficacy won’t be enough to impress investors in this sp…
  biospace · 2mo ago
• Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
  Top-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.
  biospace · 2mo ago